UNSPSC 51386612: Hydrocortisone/sulfur/zinc oxide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386612 Hydrocortisone/sulfur/zinc oxide is a Commodity code that shows a mismatch between its nominal pharmaceutical scope and the recent solicitation activity recorded under it. The single recent opportunity in the dataset—Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems—involves emergency-response pharmaceuticals and harm-reduction equipment rather than the topical dermatological compound the code nominally describes. State and local governments do solicit under dermatological codes for health department clinics, correctional facilities, and school district nursing programs, but the current activity block does not surface representative opportunities in that category.

Seminole County's IFB, posted June 30, 2026 with a response deadline of July 26, 2023, sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The procurement required vendors to absorb all shipping and delivery costs, comply with drug-free workplace and E-Verify certification, and maintain workers' compensation and professional liability insurance. The contract terms included an initial two-year award with a one-year renewal option and a three-month probationary termination clause. Potential FEMA funding introduced federal compliance requirements including adherence to the Clean Air Act and Federal Water Pollution Control Act. The source provides no evidence of additional recent opportunities under this code, no other issuing bodies, and no geographic spread beyond the single Florida solicitation.